The development of drugs for the treatment of AIDS has resulted in several potent inhibitors of human immunodeficiency virus (HIV) proteinase, of which four are currently available for clinical use (6) . The viral proteinase is responsible for the processing of viral polyproteins, an essential step in the replicative cycle of the virus (14) . Inhibition of HIV proteinase prevents maturation of the viral particle, and the virus becomes noninfectious (23) . HIV has an exceptional ability to become resistant to inhibitors targeted at viral enzymes (3) . Resistance to reverse transcriptase and proteinase inhibitors has been characterized and can generally be shown to result from specific mutations in the genes coding for the enzymes, although other resistance mechanisms can occur (4, 7, 8, 16) . The panel of resistant mutants that occurs as a result of treatment of virus or patients with a certain inhibitor is unique (20) . Cross-resistance is found when the same mutation confers resistance to different compounds. When developing antiviral drugs, an important objective is to obtain compounds that are equally efficacious against all viable mutants of the virus. So far, it has not been possible to predict the resistance profile of a certain compound. Although similar compounds are expected to result in similar resistance profiles, it is not known what structural modifications are required to result in significant changes in the resistance profile for a series of similar compounds.
A series of symmetric cyclic inhibitors of HIV type 1 (HIV-1) proteinase has been synthesized previously ( Fig. 1 ) (10) . The inhibition of purified HIV-1 proteinase by the compounds was evaluated and compared to theoretical estimates of binding affinities. One inhibitor in the series, AHA 008, was structurally very similar to the cyclic urea compound DMP 323 (15) , differing only in the linkage between the common cyclic urea core structure and the P1 and P1Ј phenyl groups. The structural difference had no great effect on affinity since approximately the same K i was found for the two compounds. DMP 323 has been followed by an analog, DMP 450, with improved pharmacokinetics. During the course of this work it was reported that DMP 450 was less efficient than DMP 323 against a mutant virus selected under the pressure of treatment with DMP 323. Therefore, in order to understand how such an inhibitor could be optimized with respect to resistance, the effects of different structural alterations need to be studied.
The aim of this study was to assess the impact of a minor structural modification on the resistance profile. AHA 008 was studied in cell cultures infected with wild-type and mutant virus and with purified wild-type and mutant HIV-1 proteinase. Virus was selected for resistance against DMP 323 (15), Ro 31-8959 (saquinavir) (5), or A-75925 (12) . Kinetic analysis of the mutants and their activities in the presence of inhibitors was used to explain the resistance profile observed in cell culture. The results give an insight into the possibility of optimizing inhibitors with respect to resistance in addition to potency.
MATERIALS AND METHODS
Inhibitors. AHA 008 was synthesized from L-mannonic ␥-lactone as described previously (10) . DMP 323 and Ro 31-8959 (saquinavir) were obtained from The Dupont Merck Pharmaceutical Company and Roche Products Ltd., respectively. A-75925 was synthesized by B. Classon (Stockholm University, Stockholm, Sweden) and I. Kvarnström and B. Samuelsson (Linköping University, Linköping, Sweden).
Cell culture studies. The effects of test compounds on HIV-infected cell culture were analyzed as described previously (19 Isolation and purification of mutant enzyme. Isolation of drug-resistant HIV proteinase was performed by two different procedures. G48V, V82A, and I84V mutants were isolated from plasmids constructed by site-directed mutagenesis, performed by a standard procedure with an Amersham RPN 1526 kit. The HIV proteinase gene (17) was restricted with EcoRI and BamHI and was inserted into M13mp18 (Boehringer Mannheim, Mannheim, Germany), and single-stranded DNA was prepared. The following oligonucleotides containing the mutations (underlined) were obtained from Operon (Alameda, Calif.): HPG48V (5Ј-CTC CAATTCCCACTATCATTTTTGG-3Ј), HPV82A (5Ј-CAATTATGTTAGCAG GTGTAGGT-3Ј), and HPI84V (5Ј-TTCTTCCAATTACGTTGACAGGT-3Ј). Positive clones were identified by sequencing before insertion into the expression vector pET11a (17) .
L90M and G48V/L90M mutants were constructed by PCR with primers and templates containing the required mutations. The template was either the wildtype gene (pGEM3ZfHP DNA) (17) or the G48V mutant gene (pGEM3ZfHPG 48V DNA). The 3Ј primer used for amplification contained the mutation (underlined) required for the L90M substitution (3Ј-primer, 5Ј-CAGAACGGATCCC TAAAATTTAAAGTGCAACCAATCTGAGTCATCAGATTTCTTCC; 5Ј-primer, 5Ј-CTTGAGAATTCATATGCCTCAGATCACTCTTTGGCAA; Operon). The PCR products were inserted into the expression vector as described previously (17) .
Expression and purification were performed by following essentially the same procedure described elsewhere (17) . Analysis of the purity of the expressed mutants was performed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis by using high-density gels and silver staining (Pharmacia, Uppsala, Sweden). The enzyme concentration was determined by measuring the absorption at 280 nm and using an extinction coefficient of 1.158 ml mg Ϫ1 cm Ϫ1 (11). A correction for inactive enzyme was made in the regression analysis used for estimation of K i values (see Results).
Kinetic studies. The kinetic constants (k cat and K m ) for the mutants were determined by using the spectrophotometric assay with a chromophoric peptide substrate described elsewhere (10) . The substrate concentration was varied over as wide a range as permitted with respect to sensitivity and solubility. The kinetic constants were estimated by nonlinear regression analysis by using SIMFIT (2) and the equation for simple Michaelis-Menten kinetics.
The effects of the inhibitors on the activity of HIV-1 proteinase was determined by a fluorometric assay with an internally quenched fluorescent peptide substrate, DABCYL-␥-Abu-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS (Bachem, Bubendorf, Switzerland). Measurements were performed in 96-well plates with a Fluoroskan plate reader (Labsystems, Helsinki, Finland). Excitation and emission wavelengths were 355 and 500 nm, respectively. All incubations were performed at 30°C in 0.1 M sodium acetate-1 M NaCl-1 mM dithiothreitol (DTT)-1 mM EDTA-3% dimethyl sulfoxide (DMSO) at pH 5.0 with 5 M substrate and the following enzyme concentrations: wild type, 1 nM; G48V, 4 nM; V82A, 6 nM; I84V, 3.5 nM; L90M, 3 nM; and G48V/L90M, 17 nM. In order to allow substrate and inhibitor to be dissolved completely, all components (300 l) were preincubated for at least 20 min before the reaction was started by adding enzyme. Initial rates were measured over 5 min. Data were analyzed by nonlinear regression by using SIMFIT (2) and an equation for tightly binding inhibitors (21), simplified as described in the Results section.
RESULTS
Inhibitory effect in cell culture. DMP 323, Ro 31-8959, and A-75925 were used for the development of resistant mutants in cell culture. Table 1 hibitors on the different virus isolates. The virus most resistant to DMP 323 was the double mutant L10F/I84V, although the single mutant I84V was also highly resistant. In contrast, Ro 31-8959 was least effective against virus with the G48V/L90M double amino acid substitution. Little effect was observed with the L90M single mutant, and the G48V single mutant was not isolated, indicating that the procedure did not favor its selection. AHA 008 showed a resistance profile similar to that of DMP 323, although resistant virus was generally less resistant to AHA 008 than to DMP 323. Both AHA 008 and DMP 323 were potent against virus (G48V/L90M) resistant to Ro 31-8959, while this compound was effective against virus resistant to the cyclic urea compounds.
Effect of inhibitors on purified HIV-1 proteinase. The mutations which appeared to be of critical importance for resistance were introduced into an expression clone of HIV-1 proteinase, and the corresponding enzymes were purified and characterized. All mutants were of high purity, as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and silver staining. The G48V, V82A, and I84V mutants were easily refolded, and the yields (8 to 10 mg/liter) were similar to those from the wild-type preparation. After refolding of mutants L90M and G48V/L90M, two-thirds of the protein content remained in a precipitate. Yields were improved by diluting the mutants to a lower protein concentration (0.3 to 0.15 mg/ml) before dialysis.
The effects of the introduced amino acid substitutions on the catalytic properties were analyzed. Table 2 presents the k cat , K m , and k cat /K m values for the different mutants studied. All of the mutant enzymes had lower catalytic efficiencies (k cat /K m ) than the wild-type enzyme. There are effects both on k cat and on K m , indicating that different amino acid substitutions alter the catalytic properties of the enzyme in different ways. Only the L90M mutant enzyme showed a lower K m than the wildtype enzyme, while the G48V/L90M double mutant enzyme was the only enzyme with a large increase in the K m value. Also, the kinetic constants were different for the two different substrates used. The effect is indicated by the k cat /K m values presented in Table 2 . The difference is mainly attributed to different affinities for the substrates since the fluorogenic substrate has a K m at least 5 times higher than that of the pnitrophenyl substrate, being greater than 70 M for the wildtype enzyme (data not shown).
An assay for accurately determining K i values for potent inhibitors was developed. In order to obtain high sensitivity combined with efficient analysis of multiple samples, a fluorescent substrate and a plate reader were used. Considering the high K m for the fluorescent substrate used, it was not possible to perform assays at saturating substrate concentrations. Measurements were therefore made under pseudo-first-order conditions, i.e., at substrate concentrations well below the K m . Activity was found to be linearly dependent on the substrate concentration when 1.25 to 10 M substrate was used. A total of 5 M substrate was routinely used. The rate equation defined for tightly binding inhibitors (21) was simplified by using [S] Ӷ K m , which after rearrangement give the following:
K i values were estimated for the test compounds by fitting this equation by nonlinear regression analysis to data obtained from assays performed with constant enzyme and substrate concentrations while varying the inhibitor concentration over a region resulting in approximately 0 to 90% inhibition. The results presented in Table 3 indicate that K i values could be estimated for all the compounds in this study; standard errors a K i values were determined by using a fluorescent substrate (DABCYL-␥-Abu-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS). All incubations were performed at 30°C in 0.1 M sodium acetate-1 M NaCl-1 mM DTT-1 mM EDTA-3% DMSO (pH 5.0) at room temperature by using 5 M substrate and the indicated enzyme concentrations ([E]). The enzyme concentration (A 280 ) was determined by absorption measurements and by using an extinction coefficient of 1.158 ml mg Ϫ1 cm Ϫ1 (11) . K m values, including standard deviations, and calculated values of the active enzyme concentrations were obtained by nonlinear regression analysis.
are also presented. Estimates of K i values were greatly influenced by the enzyme concentration used. The lowest enzyme concentration possible, with respect to sensitivity, was used in the assay. Since the catalytic properties of the mutants are different, the concentration used for each mutant was optimized separately. The concentrations are presented in Table 3 . The enzyme is known to be unstable and to loose activity upon storage and handling. The concentration determined directly after purification cannot be assumed to accurately represent the active enzyme concentration at the time of the experiment. Therefore, the regression analysis was carried out in two steps, in which the first fit was performed without fixing the enzyme concentration. For each enzyme, an average of the different estimates of the enzyme concentration was calculated and was used for the second analysis, in which the K i value was determined. Table 3 presents the concentrations obtained by the two different methods used to estimate the enzyme concentration. K i values correlate with the corresponding 50% effective doses (Table 1 ) determined with the HIV-infected cell culture.
In order to estimate the advantage of an amino acid substitution resulting in an increased K i for an inhibitor, the disadvantage of reduced catalytic efficiency must be taken into account. This can be analyzed as the ratio of K i *k cat /K m for mutant and wild-type enzymes (8) ; this ratio represents the vitality value. Table 4 presents the vitality values for the inhibitors and enzymes studied. It is clear that the I84V substitution is the most severe change in terms of resistance to both types of cyclic urea compounds, while it is less severe for the linear compound. Additionally, the I84V and V82A mutants were found to be less sensitive to DMP 323 than to AHA 008. The higher sensitivity to DMP 323 than AHA 008 for the G48V/ L90M double mutant, even when the altered catalytic efficiency is taken into account, may not be significant due to difficulties in obtaining reproducible measurements with this mutant. The lower catalytic efficiency of this mutant required an enzyme concentration higher than that required for the other mutants, making the estimation of the K i value less reliable.
The pattern of vitality values for the mutant enzymes when they are inhibited by Ro 31-8959 is different from that seen with the cyclic urea compounds. For example, G48V and G48V/L90M substitutions result in enzyme highly resistant to Ro 31-8959, while I84V and L90M substitutions have a smaller effect on resistance. In contrast, the I84V mutant was resistant to cyclic urea compounds, while enzymes containing amino acid substitutions G48V and G48V/L90M were less resistant.
DISCUSSION
The development of drugs that are efficiacious against HIV is limited by the ability of the virus to become resistant to inhibitors (3) . Compounds targeted at viral enzymes become less efficient since mutant forms of the enzyme arise, and these mutant forms are less sensitive to the inhibitors. In the presence of proteinase inhibitors a variety of different proteinase mutants appear (8, 22) . The panel of resistant mutants that occurs is unique for a certain inhibitor and cannot be predicted. Therefore, determining the resistance profile of an inhibitor is an important step in the characterization of its potential use as a drug.
We have studied the resistance profile of AHA 008 by analyzing its inhibitory effects on virus and enzymes resistant to an analogous cyclic urea compound (DMP 323) or linear analogs (Ro 31-8959 or A-75925) . The mutant found to confer resistance in virus selected in the presence of DMP 323 was I84V (Table 1) . Tisdale et al. (22) also found this mutant, while King et al. (13) selected V82F alone or in combination with other substitutions. Viral strains with enhanced resistance have additional substitutions at L97, M46 (13), or L10 (Table 1 ) (22) . The resistance profile for Ro 31-8959 was confirmed to be different from that for DMP 323, as has been shown previously (13, 22) . The two cyclic urea compounds are effective against the viral strains selected under Ro 31-8959 pressure. Since the V82 mutant was known to occur, a viral strain selected in the presence of A-75925 was used for additional reference. There was no significant effect on either of the two cyclic urea compounds or of Ro 31-8959 when V82 was mutated into alanine. Therefore, the cyclic urea compounds were found to have similar resistance profiles, as could be expected considering the small structural difference between the inhibitors. They were only less efficient against virus with I84V or L10F/I84V amino acid substitutions, in which the double mutant was approximately twice as resistant as the single mutant. Surprisingly, the mutants studied were all equally or more resistant to DMP 323 than to AHA 008.
In order to understand why the mutants showed different sensitivities to the two cyclic urea compounds, the kinetic properties of the individual enzymes were studied. Mutations found in single mutants and key mutations frequently occurring in combination with other mutations were expressed and purified for enzymatic characterization. The catalytic efficiencies (k cat / K m ) of the mutants were all reduced compared to that of the wild type. Similar results were obtained by different methods with two different substrates. All mutants showed lower k cat values, while the K m values were higher for all mutants except L90M. When L90M was combined with the G48V substitution the k cat value decreased even further while the K m value increased, resulting in the least efficient enzyme of the series. Maschera et al. (18) also found the double mutant G48V/ L90M to be much less efficient than the corresponding single mutants. Our results are similar to those reported for V82A by Lin et al. (16) and to those reported by Gulnik et al. (8) for V82A and I84V.
Inhibition of purified mutant HIV-1 proteinase by the test compounds was correlated to the effect observed in cell culture. One exception was found, however: the G48V/L90M double mutant showed similar levels of resistance to DMP 323 and AHA 008 in cell culture, while with purified enzyme little resistance to DMP 323 was observed. This discrepancy is not understood. It may be simply be a reflection of the difficulties in determining accurate K i values at the high enzyme concentration that had to be used for this mutant. The high sensitivity of the method used to determine K i values allows low enzyme concentrations to be used (0.5 nM for wild-type enzyme). This is important since the estimated K i values are on the same order of magnitude. The accuracy of the estimation is lost when the enzyme concentration is well above the K i values (equation 1). In this case, the G48V/L90M mutant enzyme was the most difficult one to purify since it did not readily refold a Vitality values were calculated according to Gulnik et al. (8) , as follows:
and its low level of activity made it necessary to use higher concentrations. We encountered the most difficulty obtaining measurements with this enzyme. The results for this enzyme should therefore not be overinterpreted. In general, the properties of resistant virus were taken to be directly correlated to the mutations in the proteinase gene, whereby other resistance mechanisms or differences in expression levels for different mutants can be disregarded in the present studies.
In order to compensate for altered kinetics of the enzymes, vitality values (8) were also calculated. The data confirm that I84V is the most severe substitution in terms of resistance against both cyclic urea compounds. As in cell culture, AHA 008 was more efficient than DMP 323 with all single mutants. As pointed out above, differences with the double mutant may not be significant. It is therefore shown that a small modification to a compound can result in modification of the typical resistance profile for the particular series of inhibitors.
The difference observed can be interpreted in structural terms for the mutant that confers the greatest resistance to DMP 323 and AHA 008. Since the I84V substitution involves replacement of a larger amino acid side chain with a smaller residue, by removing a methyl group, one would expect that the mutant renders a larger active-site cavity in S1 and S1Ј. This assumption is valid, provided that the replacement of Ile for Val does not significantly affect the conformation of the binding of the inhibitor. The inhibitor therefore appears to have sufficient room for binding, so the reduced potency should, rather, be the result of a loss of binding energy. It has been shown previously that theoretical calculations can be used to estimate binding affinities for cyclic urea compounds (10) . These calculations provide evidence that approximately 50% of the affinity can be attributed to van der Waals interactions. On the basis of X-ray crystallography, it has been proposed that favorable hydrophobic interactions are lost for DMP 323 in V82 and I84 mutants (1) . This proposal is supported by our results, in which we assumed that the weaker resistance observed for AHA 008 than DMP 323 is attributed to a smaller loss in van der Waals interactions since the linkage between the cyclic urea core structure and the phenyl ring in AHA 008 is longer than that in DMP 323.
During the course of this work it was reported that DMP 450, another analog of DMP 323, had a resistance profile similar to that for DMP 323 (9) . The K i value was close to that for DMP 323 with the wild-type enzyme, but it increased more for DMP 450 than for DMP 323 with the double mutant V82F/ I84V. It was also predicted that the I84V substitution disrupts hydrophobic interactions between the enzyme and the inhibitor. Unfortunately, the modification that resulted in a compound with better pharmacokinetic properties (DMP 450) caused increased resistance for the most critical mutant known for cyclic urea compounds. In our case, we have designed an equipotent analog with improved efficacy against this resistant mutant compared to that of DMP 323.
The data also reveal some additional features of resistance development in HIV. Failure to select for a certain mutant is not simply a reflection of the inability of the mutation to confer resistance. G48V was not found alone in resistant virus selected in the presence of Ro 31-8959 but was found only in combination with L90M. Purified enzyme with the single mutant G48V was as resistant as the G48V/L90M double mutant to the inhibitor, as judged by vitality values. Also, the importance of a second substitution (L90M) which does not interact with the inhibitor and which alone confers little resistance cannot be explained by a simple additive effect or a significant increase in effect, as seen for Ro 31-8959. Resistance to cyclic urea compounds as a result of substitutions at V82 and I84 is also affected by additional amino acid substitutions outside the active site. Therefore, these additional substitutions do not affect direct interactions between the enzyme and the inhibitor. Our results indicate that the K m for L90M is lower than that for any of the other mutants tested, while that for the double mutant G48V/L90M is the highest. This residue, situated at the dimer interface, therefore indirectly affects the binding of substrate in a manner that may be similar for certain inhibitors. The effect of substitutions of residues that do not interact directly with the inhibitors has recently been found to be important for compensating for the negative kinetic effects that result from mutations that confer resistance (22) .
In summary, these results indicate that the resistance profile can be modified by making subtle changes in the structure of the inhibitor without altering the inhibitory potency of the compound. Optimization of inhibitors should focus on potency against not only wild-type virus strains but also resistant strains. The most efficient inhibitor is that which has vitality values that are least affected by mutations. Also, it may be beneficial with respect to resistance to use closely related compounds in combination in order to suppress certain mutants.
